156 related articles for article (PubMed ID: 25997856)
1. Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.
Jager NG; Linn SC; Schellens JH; Beijnen JH
Clin Breast Cancer; 2015 Aug; 15(4):241-4. PubMed ID: 25997856
[TBL] [Abstract][Full Text] [Related]
2. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
3. Individualization of tamoxifen treatment for breast carcinoma.
Binkhorst L; van Gelder T; Mathijssen RH
Clin Pharmacol Ther; 2012 Oct; 92(4):431-3. PubMed ID: 22910442
[TBL] [Abstract][Full Text] [Related]
4. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
Zembutsu H
Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
[TBL] [Abstract][Full Text] [Related]
6. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
7. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.
de Vries Schultink AH; Zwart W; Linn SC; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2015 Aug; 54(8):797-810. PubMed ID: 25940823
[TBL] [Abstract][Full Text] [Related]
8. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
van Nuland M; Vreman RA; Ten Ham RMT; de Vries Schultink AHM; Rosing H; Schellens JHM; Beijnen JH; Hövels AM
Breast Cancer Res Treat; 2018 Nov; 172(1):143-150. PubMed ID: 30006796
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.
Neven P; Jongen L; Lintermans A; Van Asten K; Blomme C; Lambrechts D; Poppe A; Wildiers H; Dieudonné AS; Brouckaert O; Decloedt J; Berteloot P; Verhoeven D; Joerger M; Vuylsteke P; Wynendaele W; Casteels M; Van Huffel S; Lybaert W; Van Ginderachter J; Paridaens R; Vergote I; Dezentjé VO; Van Calster B; Guchelaar HJ
Clin Cancer Res; 2018 May; 24(10):2312-2318. PubMed ID: 29459457
[No Abstract] [Full Text] [Related]
12. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach.
Mueller-Schoell A; Klopp-Schulze L; Schroth W; Mürdter T; Michelet R; Brauch H; Huisinga W; Joerger M; Neven P; Koolen SLW; Mathijssen RHJ; Copson E; Eccles D; Chen S; Chowbay B; Tfayli A; Zgheib NK; Schwab M; Kloft C
Clin Pharmacol Ther; 2020 Sep; 108(3):661-670. PubMed ID: 32578187
[TBL] [Abstract][Full Text] [Related]
13. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
14. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics.
Slanař O; Hronová K; Bartošová O; Šíma M
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):307-321. PubMed ID: 33320718
[No Abstract] [Full Text] [Related]
16. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.
Binkhorst L; Kloth JSL; de Wit AS; de Bruijn P; Lam MH; Chaves I; Burger H; van Alphen RJ; Hamberg P; van Schaik RHN; Jager A; Koch BCP; Wiemer EAC; van Gelder T; van der Horst GTJ; Mathijssen RHJ
Breast Cancer Res Treat; 2015 Jul; 152(1):119-128. PubMed ID: 26050156
[TBL] [Abstract][Full Text] [Related]
17. Endoxifen shows promise in breast cancer.
Cancer Discov; 2014 Feb; 4(2):OF1. PubMed ID: 24501306
[TBL] [Abstract][Full Text] [Related]
18. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
20. [Current adjuvant endocrine treatment of breast cancer].
Dedes KJ; Gabriel N; Fink D
Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
